Literature DB >> 22990303

Angiogenesis and autosomal dominant polycystic kidney disease.

Jennifer L Huang1, Adrian S Woolf, David A Long.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the growth of multiple cysts that in many cases result in end-stage renal disease. Current strategies to reduce cyst progression in ADPKD focus on modulating cell turnover, fluid secretion, and vasopressin signalling; but an alternative approach may be to target pathways providing "general support" for cyst growth, such as surrounding blood vessels. This could be achieved by altering the expression of growth factors involved in vascular network formation, such as the vascular endothelial growth factor (VEGF) and angiopoietin families. We highlight the evidence that blood vessels and vascular growth factors play a role in ADPKD progression. Recent experiments manipulating VEGF in ADPKD are described, and we discuss how alternative strategies to manipulate angiogenesis may be used in the future as a novel treatment for ADPKD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22990303     DOI: 10.1007/s00467-012-2305-7

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  61 in total

1.  Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein.

Authors:  Miguel A Esteban; Sarah K Harten; Maxine G Tran; Patrick H Maxwell
Journal:  J Am Soc Nephrol       Date:  2006-06-14       Impact factor: 10.121

2.  Polycystin 1 is required for the structural integrity of blood vessels.

Authors:  K Kim; I Drummond; O Ibraghimov-Beskrovnaya; K Klinger; M A Arnaout
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

3.  Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease.

Authors:  Berenice Y Reed; Amirali Masoumi; Elwaleed Elhassan; Kim McFann; Melissa A Cadnapaphornchai; David M Maahs; Janet K Snell-Bergeon; Robert W Schrier
Journal:  Kidney Int       Date:  2010-09-29       Impact factor: 10.612

4.  VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice.

Authors:  Claudia R Amura; Kelley S Brodsky; Rachel Groff; Vincent H Gattone; Norbert F Voelkel; R Brian Doctor
Journal:  Am J Physiol Cell Physiol       Date:  2007-05-02       Impact factor: 4.249

5.  Lymphatic vessels develop during tubulointerstitial fibrosis.

Authors:  Izumi Sakamoto; Yasuhiko Ito; Masashi Mizuno; Yasuhiro Suzuki; Akiho Sawai; Akio Tanaka; Shoichi Maruyama; Yoshifumi Takei; Yukio Yuzawa; Seiichi Matsuo
Journal:  Kidney Int       Date:  2009-01-14       Impact factor: 10.612

6.  Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease.

Authors:  Samy Hakroush; Marcus J Moeller; Franziska Theilig; Brigitte Kaissling; Tjeerd P Sijmonsma; Manfred Jugold; Ann L Akeson; Milena Traykova-Brauch; Hiltraud Hosser; Brunhilde Hähnel; Hermann-Josef Gröne; Robert Koesters; Wilhelm Kriz
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

7.  Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors.

Authors:  Bishoy Rizkalla; Josephine M Forbes; Mark E Cooper; Zemin Cao
Journal:  J Am Soc Nephrol       Date:  2003-12       Impact factor: 10.121

8.  Angiopoietin-1 therapy enhances fibrosis and inflammation following folic acid-induced acute renal injury.

Authors:  David A Long; Karen L Price; Ella Ioffe; Claire M Gannon; Luigi Gnudi; Kathryn E White; George D Yancopoulos; John S Rudge; Adrian S Woolf
Journal:  Kidney Int       Date:  2008-05-14       Impact factor: 10.612

9.  Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism.

Authors:  Wei Mu; David A Long; Xiaosen Ouyang; Anupam Agarwal; Pedro E Cruz; Carlos A Roncal; Takahiko Nakagawa; Xueqing Yu; William W Hauswirth; Richard J Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2008-10-29

Review 10.  VEGF-A splicing: the key to anti-angiogenic therapeutics?

Authors:  Steven J Harper; David O Bates
Journal:  Nat Rev Cancer       Date:  2008-10-16       Impact factor: 60.716

View more
  6 in total

1.  The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.

Authors:  Melahat Coban; Ayca Inci
Journal:  Int Urol Nephrol       Date:  2018-04-13       Impact factor: 2.370

2.  Embolization of renal arteries before transplantation in patients with polycystic kidney disease: a single institution long-term experience.

Authors:  F Petitpierre; F Cornelis; L Couzi; A S Lasserre; E Tricaud; Y Le Bras; P Merville; C Combe; J M Ferriere; N Grenier
Journal:  Eur Radiol       Date:  2015-05-17       Impact factor: 5.315

3.  Splenic artery aneurysm in a patient of autosomal dominant polycystic kidney disease: beyond tenuous concomitance!

Authors:  Vivek Sood; Navin Pattanashetti; Krishan Lal Gupta; Raja Ramachandran
Journal:  BMJ Case Rep       Date:  2019-04-20

4.  Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium.

Authors:  Tengis S Pavlov; Daria V Ilatovskaya; Oleg Palygin; Vladislav Levchenko; Oleh Pochynyuk; Alexander Staruschenko
Journal:  J Vis Exp       Date:  2015-09-01       Impact factor: 1.355

5.  Extracranial Aneurysms in 2 Patients with Autosomal Recessive Polycystic Kidney Disease.

Authors:  Daniel S Elchediak; Anne Marie Cahill; Emma E Furth; Bernard S Kaplan; Erum A Hartung
Journal:  Case Rep Nephrol Dial       Date:  2017-05-02

6.  Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease.

Authors:  William E Sweeney; Philip Frost; Ellis D Avner
Journal:  World J Nephrol       Date:  2017-07-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.